XVI. Multiple myeloma & IV. Cell therapy workshop

Preliminary Programme


14.10.2021 - Multiple myeloma day

Opening remarks
Session I
09.45   Da Via' Matteo Claudio, University of Milan, Italy  
    „Characterization of multiple myeloma by an integrative geno-transcriptomic approach: from the genomic architecture to its functional consequences“  
10.10   Bruno Paiva, Center for Applied Medical Research, Spain  
    „New applications of next-generation flow cytometry in multiple myeloma“  
10.35   Despina Bazou, Mater Misericordiae University Hospital, Dublin, Ireland  
    „Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients“  
Coffee break
Session II
11.15   Tom Cupedo, Erasmus MC Rotterdam, The Netherlands  
    „Stromal cell-centric bone marrow inflammation in multiple myeloma“  
11.40   Eline Menu, VUB Brussels, Belgium  
    „Exosomes as key mediators in BM-MM crosstalk“  
12.05   Cirino Botta, University of Palermo, Italy  
    „Microenvironment dysregulation in multiple myeloma: novel challenges and therapeutic opportunities“  
Lunch break
Session III
13.30   Tereza Sevcikova, Blood Center Research Group, Ostrava, Czech Republic  
    „Pathogenesis of extramedullary multiple myeloma: from resistance to identification“  
13.55   Luciano Costa, University of Alabama at Birmingham, USA  
    “New Immunotherapy targets in MM clinical data”  
14.20   Francesco Maura, Sylvester Comprehensive Cancer Center, University of Miami, USA  
    "Multiple myeloma genomic defining events"  
14.45   Morie Gertz, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA  
    „Diagnosis, prognosis and therapy of immunoglobulin light chain amyloidosis“  
Closing remarks for the day
Social event


Session IV
9.30   Caroline Heckman, Institute for Molecular Medicine Finland  
    “Functional precision medicine for biomarker discovery and treatment support of relapsed/refractory myeloma patients”  
9.55   Tomas Jelinek, Blood Cancer Research Group, Ostrava, Czech Republic  
    "Circulating plasma cells as critical diagnostic marker in the newly diagnosed multiple myeloma"  
10.20   Marcello Turi, Blood Cancer Research Group, Ostrava, Czech Republic  
    “Connection between autophagy and oncogenic MyD88 signaling”  
Coffee break
Session I
11.15   Michael Hudecek, University of Würzburg, Germany  
    „New targets and technologies for CAR-T cell therapy“  
11.45   Monika Holubová, Fakultní nemocnice Plzeň, Czech Republic  
    „NK cells immunotherapy in multiple myeloma“  
12.10   Leo Rasche, Universty of Wurzbzrg, Germany  
    „Delineating tumor heterogeneity in the era of novel immunotherapies in multiple myeloma“  
12.35   Sophia Adamia, Dana-Farber Cancer Institute, USA  
    „Alternative RNA processing prospective RNA toolkit in myeloma cell therapy“  
Lunch break
Special session
14.00   Kenneth Anderson, Dana-Farber Cancer Institute, USA  
    Session II  
14.35   Michal Smida, Citec, Brno, Czech Republic  
    „CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cells“  
15.00   Piotr Celichowski, Blood Cancer Research Group, Ostrava, Czech Republic  
    „Allogenic CAR-T cells“  
15.25   Michael O'Dwyer, National University of Ireland, Ireland  
    „The role of NK cells in treatment of multiple myeloma“  
Closing remarks